XOMA Royalty Corp

XOMA Royalty Corporation operates as a biotech royalty aggregator, holding economic rights to milestone and royalty payments from therapeutic candidates in development and commercialization. The company's portfolio consists of early to mid-stage clinical assets primarily in Phase 1 and 2 that are licensed to external partners, as well as late-stage clinical or commercial assets where it has acquired milestone and royalty revenue streams. This model allows the company to generate non-dilutive revenue from partnered drug development programs without direct responsibility for clinical execution or regulatory approval.

The company's revenue derives from two primary sources: milestone payments triggered by clinical, regulatory, or commercial achievements on partnered assets, and ongoing royalties on commercial sales of approved drugs. The portfolio spans multiple therapeutic areas with assets at various development stages, generating a diversified stream of potential payments as partner companies advance their programs.

Based in Emeryville, California, XOMA Royalty operates with a lean organizational structure of 13 full-time employees. The company maintains a geographic footprint across the United States and Asia Pacific regions. Originally incorporated in 1981 and previously known as XOMA Corporation, the company underwent a strategic transformation and rebranding to XOMA Royalty Corporation in July 2024 to better reflect its focus on royalty and milestone acquisition.